CALIWAY BIOPHARMACEUTICALS CO., LTD.

Otros idiomas Caliway Biopharmaceuticals Co., Ltd.

Acciones

6919

TW0006919004

Precio de cierre Taipei Exchange Otros sitios de cotización 00:00:00 29/05/2024			Varia. Cinco días.	Varia. 1 de enero.
413,5 ^TWD	+0,12 %		-2,13 %	+116,21 %

25/04	Caliway Biopharmaceuticals Co. anuncia que el estudio de fase 2 CBL-514 para el tratamiento de la celulitis alcanzó todos los criterios de valoración primarios y secundarios	CI
04/03	Caliway Biopharmaceuticals Co. Ltd. informa de los resultados del ejercicio finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints	25/04
Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease	05/03
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease	15/02
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug	24/01
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction	23/01
Caliway Biopharmaceuticals Gets US FDA Nod for Phase 2 Trial of Dercum's Disease Drug	09/01
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease	08/01
Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding	16/12
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study	02/10/23
Caliway Biopharmaceuticals Completes Recruitment for Severe Cellulite Drug Study	20/09/23
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7	13/09/23
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11/08/23
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite	28/06/23
Caliway Biopharmaceuticals Co., Ltd.(TPEX:6919) added to S&P Global BMI Index	19/06/23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	31/05/23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	31/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Bolsa de valores
Acciones
Acción 6919
Noticias Caliway Biopharmaceuticals Co., Ltd.
Otros idiomas

-40% Oferta por Tiempo Limitado: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.

APROVÉCHELO AHORA